RxDoctor Payments Data

Jill Hunt

Adult Health · Bangor, MENPI 1861053852

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,280 of the $4,860 with a category attached, or 67.5%. 23 manufacturers reported payments, led by Medtronic at 52.6% of the total. Reporting peaked in 2022 at $2,516 and has fallen 97.5% since, to $62 in 2025. Among adult health clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,860in general payments, 2019–2025

Across 86 payments — averaging $56.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Acadia Pharmaceuticals Inc$560
  • AstraZeneca$296
  • AbbVie$260
  • Stryker$216
  • Takeda Pharmaceuticals U.S.A., Inc.$128
  • plus $844 from 17 others

What the payments were for

  • Travel & lodging$1,58033%
  • Food & beverage$3,28067%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,860 in reported general payments places this provider in the 95th percentile of 51 adult health providers in Maine.

See all adult health providers in Maine

Medicare billing

Part B allowed, 2024
$14,322
Medicare patients
86
Services billed
361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Albuterol Sulfate HfaAlbuterol Sulfate11$765
Gabapentin32$338
Rosuvastatin Calcium13$329
Atorvastatin Calcium30$291
Levothyroxine Sodium21$235
Irbesartan14$218
Metoprolol Succinate13$176
Lisinopril17$80
Oxycodone Hcl13$75
Tizanidine Hcl11$66
Meloxicam12$46
Cyclobenzaprine Hcl21$39
Tramadol Hcl11$38
Amlodipine Besylate14$11

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCLevothyroxine Sodium$121$23521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 51 adult health providers in Maine.

Other adult health in Bangor

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →